Erythropoietin stimulates proliferation of human renal carcinoma cells
| Autor: | R. L. Baranowski, Christof Westenfelder |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
medicine.medical_specialty von Hippel-Lindau Disease Transcription Genetic Angiogenesis Gene Expression Biology Iodine Radioisotopes Kidney Tubules Proximal angiogenesis Mice proliferating cells hemic and lymphatic diseases Internal medicine Receptors Erythropoietin Tumor Cells Cultured medicine Carcinoma Animals Humans RNA Messenger Receptor Carcinoma Renal Cell Erythropoietin Mice Inbred BALB C Kidney Neovascularization Pathologic Cell growth Membrane Proteins Anemia Middle Aged medicine.disease Kidney Neoplasms medicine.anatomical_structure Endocrinology tumor malignancy Nephrology Cell culture Cancer research Mitogens Cell Division Clear cell Adenocarcinoma Clear Cell medicine.drug |
| Zdroj: | Kidney International. 58:647-657 |
| ISSN: | 0085-2538 |
| DOI: | 10.1046/j.1523-1755.2000.00211.x |
| Popis: | Erythropoietin stimulates proliferation of human renal carcinoma cells. Background We reported recently that normal human, rat, and mouse tubular cells express authentic erythropoietin-receptors (EPO-R) through which EPO stimulates mitogenesis. The present study examines whether EPO could elicit such a proliferative and thereby potentially detrimental response in cells of human renal-cell carcinoma (RCC). Methods Nephrectomy samples were screened from patients with RCC (one chromophilic, two clear cell) as well as cell lines of human (Caki-2, 786-0) and mouse (RAG) renal adenocarcinomas for expression of EPO-R transcripts and protein. Cells were further tested for specific 125 I-EPO binding and mitogenic response to EPO. Results Authentic EPO-R transcripts and protein (approximately 72 kD) were detected in renal tumors and cell lines. Tumors showed low-level EPO expression, while cell lines did not. In cells, specific 125 I-EPO binding to a single class of EPO-R (apparent K d 1.3 to 1.4 nmol/L, B max 2.2 to 2.6 fmol/mg protein) was observed. EPO stimulated cell proliferation dose dependently, and the individual mitogenic effects of either EPO or 10% newborn calf serum were markedly amplified when both were coadministered. Conclusion These data are the first to demonstrate, to our knowledge, that human RCCs express EPO-R message and protein and that receptor activation stimulates their proliferation in vitro. If these mitogenic effects of EPO are also operative in patients with RCC, endogenous EPO or its administration for the treatment of anemia could potentially hasten proliferation of renocellular malignancies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|